Triple-negative breast cancer (TNBC) has a relatively poor outcome. Acquired chemoresistance is a major clinical challenge for TNBC patients. Previously, we reported that kinase-dead Aurora kinase A (Aurora-A) could effectively transactivate the FOXM1 promoter. Here, we demonstrate an additional pathway through which Aurora-A stabilizes FOXM1 by attenuating its ubiquitin in TNBC. Specifically, Aurora-A stabilizes FOXM1 in late M phase and early G1 phase of the cell cycle, which promotes proliferation of TNBC cells. Knock-down of Aurora-A significantly suppresses cell proliferation in TNBC cell lines and can be rescued by FOXM1 overexpression. We observe that paclitaxel-resistant TNBC cells exhibit high expression of Aurora-A and FOXM1. Overexpression of Aurora-A offers TNBC cells an additional growth advantage and protection against paclitaxel. Moreover, Aurora-A and FOXM1 could be simultaneously targeted by thiostrepton. Combination of thiostrepton and paclitaxel treatment reverses paclitaxel resistance and significantly inhibits cell proliferation. In conclusion, our study reveals additional mechanism through which Aurora-A regulates FOXM1 and provides a new therapeutic strategy to treat paclitaxel-resistant triple-negative breast cancer.
| INTRODUC TI ON
Triple-negative breast cancer (TNBC) represents 15%-20% of newly diagnosed breast carcinoma and is characterized by low expression of progesterone receptor (PR), oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2). [1] [2] [3] Patients with TNBC have a relatively poor outcome and cannot be treated with endocrine therapy or therapies targeted to HER2. Thus, to date, chemotherapy remains the only possible therapeutic option in the treatment of TNBC. 4, 5 Paclitaxel is one of the most frequently used chemotherapeutic drug for TNBC. 6 It disrupts normal microtubule dynamics and arrests cancer cells in mitosis. Although TNBC patients are initially responsive to paclitaxel, acquired chemoresistance is inevitable and put forward a major clinical challenge for patients that relapsed. 7, 8 Thus, to elucidate the molecular mechanism of paclitaxel resistance and develop new combination drug therapy for TNBC are urgently needed to decrease TNBC-related mortality.
Aurora kinase A (Aurora-A) is a member of a serine/threonine kinase family involved in mitotic cell division and genetic instability. 9 Overexpression of Aurora-A has been reported to participate in multi-drug resistance. [10] [11] [12] Several studies have shown that aberrant expression of Aurora-A is highly correlated with triple-negative breast cancer (TNBC) and was a potential therapeutic target for TNBC. 3, [13] [14] [15] Aurora-A exerts its function in cancer through kinase-dependent and kinase-independent manner. In human neuroblastoma, Aurora-A stabilizes N-Myc and contributes to the development of neuroblastoma independently of its kinase activity. 16 Aurora-A was also reported to phosphorylate YAP and promotes YAP-mediated transcription in TNBC. 15 We reported previously that kinase-dead Aurora-A can play as a transcriptional co-factor in nucleus to transactivate the FOXM1 promoter in breast cancer stem cell. 17 FOXM1 was reported to mediate drug resistance and was highly up-regulated in TNBC. 18, 19 To elucidate the underlying mechanism for Aurora-A regulating FOXM1 in TNBC is important for the targeted therapy that aiming to block the critical oncogenic function of Aurora-A.
In the present study, we demonstrate that Aurora-A binds and stabilizes FOXM1 protein independently of its kinase activity. This function is critical for the growth of TNBC cells. We observed that overexpression of Aurora-A mediated paclitaxel resistance in TNBC cells. Moreover, Aurora-A and FOXM1 could be simultaneously targeted by thiostrepton which could overcome paclitaxel resistance in TNBC cells. Finally, aberrant expression of FOXM1 and Aurora-A was found highly correlated in human triple-negative breast cancer sample. Overall, our studies revealed additional mechanism through which Aurora-A regulates FOXM1 and provided a new combination drug therapeutic strategy to treat paclitaxel-resistant triple-negative breast cancer. 
| MATERIAL S AND ME THODS

| Cell culture and cell cycle arrest
| Gene knock-down using shRNA and siRNA
Gene silencing was performed using specific shRNAs delivered by a lentiviral system acquired from Sigma-Aldrich (Shanghai, China), following the instructions provided. Briefly, to yield lentiviruses containing specific shRNA sequences, 293T cells were cotransfected with 2.5 μg pMD2.G and 7.5 μg psPAX2 packaging plasmids Membrane was incubated in primary antibodies at 4°C overnight.
| IP and Western blot analysis
The membranes were then incubated for 1 hour at room temperature with the appropriate secondary antibodies. Proteins were detected with an enhanced chemiluminescence kit (Pierce, ThermoFisher Scientific).
| Real-time RT-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen), and used for generating cDNA using SuperScript III RT (Invitrogen) in the presence of oligo-dT primers. Real-time reverse transcriptase-PCR was performed using Platinum SYBR Green qPCR Super-Mix (Invitrogen),
with GAPDH (glyceraldehyde 3-phosphate dehydrogenase) as the internal control. 
| Immunohistochemical staining
| Statistical analysis
Statistical analyses were performed using the SPSS software, version 16 .0 (SPSS Inc) and with GraphPad Prism 5.0 (GraphPad Software Inc). The unpaired Student's t test was used to perform statistical analysis between two groups. Continuous and categorical variables were compared between groups, using the Mann-Whitney test and one-way ANOVA for non-parametric continuous data. Pearson's correlation coefficient (r) was used to describe the correlation between two variables. A value of P < .05 was considered statistically significant. The UALCAN web resource was used for analysing cancer transcriptome data in TCGA database. 
| RE SULTS
| Aurora-A and FOXM1 are overexpressed and correlated in triple-negative breast cancer
To investigate the significance of Aurora-A and FOXM1 in breast cancer, we evaluate cancer transcriptome in TCGA database at UALCAN web resource. 21 As shown in Figure 1A , Aurora-A is over- in breast cancer (r = .53, P < .01; Figure 1E ). Next, we analysed the expression level of Aurora-A and FOXM1 in a panel of 66 TNBC samples and 11 benign breast tumour samples from GuangZhou First
People' hospital. Aurora-A was highly expressed in 54 samples and lowly expressed in 12 samples while FOXM1 was highly expressed in 43 samples and lowly expressed in 23 samples. Aurora-A and FOXM1 were co-expressed in 39 TNBC samples, which was consistent with the TCGA database (P < .05; Figure 1F ). The representative picture of high expression and low expression was shown in Figure 1G . Together, our data suggest that Aurora-A and FOXM1 are co-expressed in clinical TNBC samples, supporting the critical role of Aurora-A and FOXM1 in TNBC growth.
| Aurora-A stabilizes FOXM1 during cell cycle
Next, we test whether Aurora-A regulates FOXM1 in TNBC cells, were critical cell cycle protein of G2/M phase, we test whether F I G U R E 1 Aurora-A and FOXM1 are overexpressed and correlated in triple-negative breast cancer. A, Transcript of Aurora-A was evaluated in breast cancer in TCGA database. Triple-negative breast cancer is defined by low or no expression of progesterone receptor (PR), oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2 si-control and si-Aurora-A small RNA. Subsequently, MG-132 was added to cells at last 6 h and lysates were analysed by Western blot. E, Cells were arrested at the G1-S boundary by double thymidine block, released into fresh medium, and harvested at the indicated times. Cell lysates were subjected to Western blot assays with indicated antibodies. F, Cells were released from nocodazole block (prometaphase) for the indicated times. Cell extracts were subjected to Western blotting with indicated antibody. G, Cells were transfected with si-control and si-Aurora-A small RNA, and real-time RT-PCR was performed to evaluate the M phase cell cycle genes Aurora-A regulates FOXM1 during cell cycle. After cells were synchronized in G1/S phase by a double thymidine block, protein extracts were prepared at indicated time-point following thymidine removal and analysed by immunoblotting. As shown in Figure 2E (lane 2 to 6), the level of FOXM1 increased during the late S phase (after 3 hours of thymidine removal) and the transition between G2 phase and mitosis (at the time-point of 9-12 hours). Aurora-A and FOXM1 were simultaneously accumulated gradually from S phase to G2 phase and peaked in mitosis. Interestingly, both Aurora-A and Figure 5D ), arguing that Aurora-A regulates FOXM1 levels via both transcription and posttranscriptional mechanisms in TNBC cells. We concluded that Aurora-A up-regulating FOXM1
| Aurora-A directly binds and attenuates ubiquitin of FOXM1
was essential for the growth of TNBC cells.
| Aurora-A enhances paclitaxel resistance in triple-negative breast cancer
Previous study reported that FOXM1 mediates resistance to paclitaxel. 22 We sought to investigate whether increased Aurora-A induces resistance to paclitaxel. To prove the hypothesis, we sta- Studies from ours and others reported that the antibiotic drug thiostrepton targeted FOXM1 and greatly inhibited growth of TNBC cells. 23, 24 We sought to explore whether thiostrepton could reverse paclitaxel resistance. Notably, both Aurora-A and FOXM1
were reduced when treated with thiostrepton alone or in combination with paclitaxel ( Figure 6E , lane 4 and lane 5). However, combination treatment with paclitaxel and Aurora-A kinase inhibitor VX-680 has slight effect on Aurora-A and FOXM1 levels.
Proliferative assays showed that paclitaxel-resistant cells exhibited a significant decrease in cell viability when treated with thiostrepton alone or in combination with paclitaxel ( Figure 6F ). These results indicated that Aurora-A confers resistance by up-regulating FOXM1. It is worth to mention that Aurora-A kinase inhibitor VX680 in combination with paclitaxel can significantly inhibit growth of resistant cells, which indicated other mechanisms may account for VX680 effect.
| D ISCUSS I ON
We reported here that Aurora-A promotes proliferation of TNBC cells by stabilizing FOXM1. Knock-down of Aurora-A significantly suppressed cell proliferation and colony formation in TNBC cell lines. Notably, Aurora-A-mediated reduced colony formation was rescued by FOXM1 overexpression, indicating that the reduction in FOXM1 levels is the critical mechanism by which depletion of Aurora-A inhibits proliferation, and this function is critical for the growth of TNBC cells. We also observed that aberrant expression of FOXM1 and Aurora-A is highly correlated in clinical TNBC samples, providing clinical evidence for Aurora-A regulating FOXM1 in TNBC.
Depletion of Aurora-A in MDA-MB-231 cells not only reduced the steady-state levels of FOXM1 protein but also led to decrease in FOXM1 mRNA levels ( Figure 4D ), arguing that Aurora-A regulates cells, such as MCF-7, the kinase activity of Aurora-A is probably important, as FOXM1 is obviously down-regulating by Aurora-A kinase inhibitor VX680. Thus, inhibition of Aurora-A kinase activity using small molecules may not enough to block a critical oncogenic function of Aurora-A in triple-negative breast cancer. Indeed, several studies were currently being evaluated in preclinical models of TNBC. [25] [26] [27] [28] Some models are sensitivity to ENMD-2076, a kinase inhibitor of Aurora-A, by induction of apoptosis, whereas some models exhibiting intrinsic or acquired resistance to treatment. 26 The result from our study suggested that inhibition of both kinase-dependent and kinase-independent function is required for TNBC patients. 29, 37, 38 In normal cell cycle, FOXM1 is synthesized and degraded in every cycle of cell division. It is reported that FOXM1 is polyubiquitinated by APC/CCdh1 for degradation by the proteasome in late mitosis and early G1-phase. 20 The degradation of FOXM1 in the late mitosis and early G1-phase is important for regulated entry into S phase. Previous study reported that FOXM1 exhibited obvious reduction after 3 hours of nocodazole removal (late mitosis and early G1 phase). 20, 39 We observed that the High expression of Aurora-A was reported a predictive maker for poor prognosis and drug resistance in triple-negative breast cancer, which is associated with a greater risk of recurrence and relapse. 13, 14, 40 22 We observed that FOXM1 was also up-regulated in paclitaxel-resistant cells. Combination of FOXM1 inhibitor thiostrepton and paclitaxel treatment can reverse acquired paclitaxel resistance in TNBC cells and significantly inhibiting cell proliferation. These results show the likely mechanism by which Aur-A confers resistance is by preventing the degradation of FOXM1, and this function is kinase independent. A study using in vivo model of triple-negative breast cancer reported that Aurora-A kinase inhibitor MLN8237 and taxanes have synergistic antitumour activity. 51 We also found a synergistic activity between VX680 and paclitaxel in TNBC cells, indicating other mechanisms are involved in the antitumour activity of aurora kinase inhibitor. Interestingly, the Aurora-A and FOXM1 could be simultaneously reduced by thiostrepton in paclitaxel-resistant TNBC cells. Together, our result suggested that thiostrepton inhibited growth of paclitaxel-resistant cells by down-regulating both Aurora-A and FOXM1 and could be a therapeutic strategy for reversing paclitaxel chemoresistance in TNBC patients.
Overall, the mechanism we revealed in this study provided insight into an additional pathway through which Aurora-A regulates FOXM1 in triple-negative breast cancer. Aurora-A-mediated stabilization of FOXM1 could reflect its kinase-independent role in enhanced proliferation capacity of TNBC cancer cells. Although inhibition of Aurora-A kinase was a promising regimen for TNBC cancer therapy, the results presented here suggested that the use of an antibiotic drug thiostrepton, which is capable of directly down-regulating Aurora-A and FOXM1 level, could synergize with paclitaxel to reverse paclitaxel chemoresistance in TNBC. Our findings provide evidence for using thiostrepton as a new therapeutic strategy for paclitaxel-resistant TNBC patients. 
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